dBRD 9-A
Based on 1 Customer Validation
dBRD 9-A is a selective BRD9 PROTAC degrader. dBRD 9-A induces near complete BRD9 degradation dependent on E3 ubiquitin ligase CRBN and BRD9 bromodomain engagement, and drives loss of BRD9 chromatin binding genome-wide. dBRD 9-A downregulates oncogenic SS18-SSX-driven transcriptional programs, super enhancer-associated gene expression, and SS18-SSX1 super enhancer binding, and depletes GBAF complex members GLTSCR1/1L from SS18-SSX complexes. dBRD 9-A induces cell cycle arrest and increases apoptosis in synovial sarcoma cells. dBRD 9-A can be used for the research of synovial sarcoma.
(Pink: BRD9 ligand (HY-107446); Blue: Cereblon ligand (HY-14658); Black: linker).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.07%
- CAS. Nr.: 2170679-42-0
- Formel: C42H49N7O8
- Molecular Weight:779.88
-
Speicherung:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle PROTACs Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
BRD9 |
In Vitro
dBRD9-A (100 nM; 6-72 h) induces near complete degradation of BRD9 in HSSYII and SYO1 synovial sarcoma cells[1].
dBRD9-A (100 nM; 24 h) leads to a near-complete loss of BRD9 chromatin binding genome-wide in HSSYII synovial sarcoma cells[1].
dBRD9-A (100 nM; 3-9 days) induces a progressive cell cycle arrest characterized by accumulation of G1/G0 phase cells and reduction of S phase cells in HSSYII and SYO1 synovial sarcoma cells[1].
dBRD9-A (100 nM; 3-9 days) induces a progressive increase in apoptotic cells in HSSYII and SYO1 synovial sarcoma cells[1].
dBRD9-A (100 nM; 6 h) primarily induces downregulation of gene expression, with preferential downregulation of genes associated with super enhancers in HSSYII synovial sarcoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HSSYII, SYO1
-
Concentration:100 nM
-
Incubation Time:6 h, 12 h, 24 h, 48 h, 72 h
-
Result:Elicited near complete BRD9 degradation across all tested time points in both HSSYII and SYO1 cell lines.
-
Cell Line:HSSYII, SYO1
-
Concentration:100 nM
-
Incubation Time:3 days,6 days,9 days
-
Result:Induced a progressive cell cycle arrest, with increases in G1/G0 phase cells and decreases in S phase cells over time in both cell lines.
-
Cell Line:HSSYII, SYO1
-
Concentration:100 nM
-
Incubation Time:3 days,6 days,9 days
-
Result:Resulted in a progressive increase in Annexin-V positive (apoptotic) cells over time in both cell lines.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (Foxn1nu) (female, 4-6 weeks old, subcutaneous xenograft model) injected with synovial sarcoma cells[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily; 24 days
-
Result:Inhibited tumor progression over 24 days, with a significant difference in tumor volume compared to vehicle control.
Confirmed near-complete degradation of BRD9 in tumor tissue via western blotting.
Retained normal body weight and blood counts, with no overt treatment-related side effects.
Chemical Information
-
CAS. Nr. 2170679-42-0
-
Appearance Solid
-
Molecular Weight 779.88
-
Formel C42H49N7O8
-
Color Light yellow to yellow
-
SMILES
O=C1C2=C(C(C3=CC(OC)=C(CN(CC(NCCCCCCCCNC4=CC=CC(C(N5C6C(NC(CC6)=O)=O)=O)=C4C5=O)=O)C)C(OC)=C3)=CN1C)C=CN=C2
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : 100 mg/mL (128.22 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2822 mL | 6.4112 mL | 12.8225 mL | 32.0562 mL |
| 5 mM | 0.2564 mL | 1.2822 mL | 2.5645 mL | 6.4112 mL | |
| 10 mM | 0.1282 mL | 0.6411 mL | 1.2822 mL | 3.2056 mL | |
| 15 mM | 0.0855 mL | 0.4274 mL | 0.8548 mL | 2.1371 mL | |
| 20 mM | 0.0641 mL | 0.3206 mL | 0.6411 mL | 1.6028 mL | |
| 25 mM | 0.0513 mL | 0.2564 mL | 0.5129 mL | 1.2822 mL | |
| 30 mM | 0.0427 mL | 0.2137 mL | 0.4274 mL | 1.0685 mL | |
| 40 mM | 0.0321 mL | 0.1603 mL | 0.3206 mL | 0.8014 mL | |
| 50 mM | 0.0256 mL | 0.1282 mL | 0.2564 mL | 0.6411 mL | |
| 60 mM | 0.0214 mL | 0.1069 mL | 0.2137 mL | 0.5343 mL | |
| 80 mM | 0.0160 mL | 0.0801 mL | 0.1603 mL | 0.4007 mL | |
| 100 mM | 0.0128 mL | 0.0641 mL | 0.1282 mL | 0.3206 mL |